CytRx Unveils Clinical Development Plan For Pipeline Assets (PharmaceuticalOnline)

CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets.

Teens 'miss out' on cancer trials (BBC News)

Teenagers with cancer are excluded from clinical trials which could improve their survival chances, UK research shows.

Commercialisation Of Yondelis(R) For The Treatment Of Soft Tissue Sarcoma Approved In Russia (Medical News Today)

The Russian regulatory body has approved YONDELIS® (trabectedin) for the treatment of soft tissue sarcoma in adults. This represents another approval for YONDELIS® for treatment soft tissue sarcoma (STS) following upon its approval in Europe in September 2007, which opens up new opportunities in markets with enormous growth potential.

New Cancer Treatment Shrinks Pancreatic Tumor (Medical News Today)

A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis.

PharmaMar Receives "Supporting A Cure In Our Time" Sarcoma Foundation Of America Award For Commitment With Research In ... (Medical News Today)

PharmaMar has received the Award "Supporting A Cure In Our Time" from the Sarcoma Foundation of America (SFA) for its "support in the search for an effective cure for soft tissue sarcomas," goal of the foundation, during the congress of the Connective Tissue Oncology Society (CTOS) held in London from 13-15 November.

PharmaMar gets 'Supporting A Cure In Our Time' award from SFA (PharmaBiz)

Copyright © Saffron Media Pvt. Ltd. Designed & Maintained by Fast Cursor

Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment (Medical News Today)

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment.

Relapsed Ovarian Cancer - Submitted New Drug Application To FDA For Trabectedin (Medical News Today)

PharmaMar announced today that Ortho Biotech Products, L.P. has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL® (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer (ROC).

Common Virus Helps Quality Of Life For Sarcoma Patients Says Cancer Expert (Medical News Today)

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives. Dr.

Common Virus Helps Quality of Life for Sarcoma Patients Says Cancer Expert (Newswise)

New data presented by Dr. Monica Mita at the Cancer Therapy and Research Center at the University of Texas Health Science Center, shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

Recent advances in cancer stem/progenitor cell research: therapeutic...

Abstract Introduction Functions of cancer progenitor cells in the cancer initiation and progression New model of carcinogenesis based on the cancer progenitor cells Isolation and ex vitro and in vivo ...

The Forgotten Cancer - European Patient Group Formed

European advocacy and support groups working with patients who have some of the rarest cancers have agreed to form a collaborative association.

Types of Cancers- Risk Factors and Treatment

The exact cause of cancer is not known but researchers believe the causes are as a result of an interaction between the individual's genes and the environment.

Birthday boy's big-hearted gift

ONE satisfied patient has said thank you for the care he received at Morriston Hospital by donating his 80th birthday presents to the staff.

St. Baldrick's Foundation announces $330,000 in funding of St....

St. Baldrick's Foundation , a nonprofit organization dedicated to raising money for childhood cancer research, recently awarded $330,000 to fund Alex Huang, M.D., Ph.D., of the Case Western Reserve University ...

Pediatric Oncology Research Boosted By $330,000 Funding Of Scholar At Case Western Reserve

Main Category: Cancer / Oncology Also Included In: Pediatrics / Children's Health Article Date: 27 Oct 2008 St.

BSD Medical Corp. Announces ESMO Recommends Hyperthermia as 'Standard ...

BSD Medical Corp. announced today that the addition of hyperthermia to chemotherapy was recommended as standard therapy for soft tissue sarcoma by the European Society for Medical Oncology , the leading ...

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial

Results and Preclinical Research at Upcoming Conferences CALGARY, Sept. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical ...

CALGARY, Sept. 22 /CNW/ - Oncolytics Biotech Inc. today announced the participation of five of its collaborators and their schedule of presentations at four conferences through November 15, 2008 covering ...

Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating...

Threshold Pharmaceuticals, Inc. , today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.